Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2008

Akrimax Purchases Wyeth’s Rouses Point Facility

  • Akrimax Pharmaceuticals bought Wyeth’s drug manufacturing and packaging plant in Rouses Point, NY. In late 2005, Wyeth decided to phase out operations at this site. Akrimax’ acquisition thus averts closure of the plant.

    Wyeth and Akrimax will have a cooperative relationship during a transition period that will conclude at the end of 2009. During this time, Akrimax will lease the facility back to Wyeth, so that Wyeth can continue manufacturing its products, while Akrimax begins integrating its own products into the facility.

    “Our plan is to develop, manufacture, and distribute pharmaceutical products from our own product portfolio and other third-party contracts,” says Joseph Krivulka, one of the Akrimax founders.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »